CTI BioPharma Corp.
CTICNASDAQHealthcare
$9.10
+$0.01(+0.06%)
Market Cap$1.2B
P/E Ratio—
52W High$9.1
52W Low$4.01
CTI BioPharma Corp. (CTIC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTIC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $53.95M | $0.00M | $0.00M | $3.35M | $26.29M |
| Cost of Revenue | $3.51M | $0.16M | $4.20M | $0.00M | $0.88M |
| Gross Profit | $50.43M | ($0.16M) | ($4.20M) | $3.35M | $25.41M |
| Gross Margin %(computed) | 93.49% | — | — | 100.00% | 96.66% |
| Operating Expenses | |||||
| R&D Expenses | $36.90M | $39.14M | $25.94M | $24.11M | $36.47M |
| G&A Expenses | $0.00M | $0.00M | $17.63M | $0.00M | $0.00M |
| Total Operating Expenses | $130.23M | $95.33M | $47.77M | $43.26M | $57.65M |
| Operating Income | ($79.80M) | ($95.33M) | ($47.77M) | ($40.71M) | ($32.90M) |
| Operating Margin %(computed) | -147.91% | — | — | — | -125.14% |
| Interest Income | $1.68M | $0.04M | $0.20M | $1.17M | $1.22M |
| Interest Expense | $13.14M | $2.42M | $1.03M | $1.52M | $1.73M |
| Income Before Tax | ($92.99M) | ($97.91M) | ($52.45M) | ($40.02M) | ($29.35M) |
| Income Tax Expense | ($1.95M) | $1.73M | $0.50M | $2.29M | $5.28M |
| Net Income | ($91.04M) | ($99.64M) | ($52.95M) | ($42.32M) | ($29.32M) |
| Net Margin %(computed) | -168.76% | — | — | — | -111.53% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.79 | $-1.11 | $-0.74 | $-0.73 | $-0.52 |
| Wtd Avg Shares | 114.69M | 90.12M | 71.14M | 57.97M | 56.07M |
| EBITDA | ($79.85M) | ($95.33M) | ($51.22M) | ($37.42M) | ($32.90M) |
| EBITDA Margin %(computed) | -148.02% | — | — | — | -125.14% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more CTI BioPharma Corp. data
About CTI BioPharma Corp. (CTIC) Income Statement
CTI BioPharma Corp. (CTIC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, CTIC reported revenue of $0.05B, gross profit of $0.05B (gross margin 93.49%), and net income of ($0.09B) — a net profit margin of -168.76%.
Frequently asked questions
CTIC · 4 questionsCTI BioPharma Corp. (CTIC) reported revenue of $0.05B for 2022, up —% year-over-year.
CTIC revenueCTIC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09